SOX10 and melanoma: Interestingly, the targeted inhibitors of the MAPK signaling pathway, which are successfully being used in clinical routine, did not alter SOX10 levels in primary melanoma cultures in vitro, nor in vivo in human patient samples, suggesting that maintaining SOX10 levels might be a mechanism of later, acquired resistance.